rimegepant

In final report, ICER appears to have a change of heart on new acute migraine therapies
In final report, ICER appears to have a change of heart on new acute migraine therapies
Endpoints
ICER
migraines
Biohaven
Allergan
ubrogepant
rimegepant
Eli Lilly
Lasmiditan
Flag link:
New Meds Set to Reshape US CNS and oncology Markets
New Meds Set to Reshape US CNS and oncology Markets
Xconomy
CNS
oncology
cancer
Clarivate Analytics
Biohaven
rimegepant
Novartis
OMB-157
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Fierce Pharma
FDA
migraines
cholesterol
Epizyme
tazemetostat
Esperion
bempedoic acid
teprotumumab
Horizon Therapeutics
Biohaven
rimegepant
Flag link:
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
Fierce Pharma
Biohaven
migraines
CGRP blockers
rimegepant
Flag link:
Biohaven is betting hundreds of millions it can hustle ahead of rivals in a blockbuster race. A quick M&A deal could pay off backers big time
Biohaven is betting hundreds of millions it can hustle ahead of rivals in a blockbuster race. A quick M&A deal could pay off backers big time
Endpoints
Biohaven
migraines
rimegepant
Flag link:
Racing Allergan, Biohaven Touts Migraine Drug Data, But Shares Sink
Racing Allergan, Biohaven Touts Migraine Drug Data, But Shares Sink
Xconomy
Allergan
Biohaven Pharmaceuticals
migraines
rimegepant
Flag link: